Ernexa Therapeutics Inc (NASDAQ: ERNA) has experienced a rise in its stock price by 13.11 compared to its previous closing price of 0.22. However, the company has seen a gain of 19.66% in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas.
Is It Worth Investing in Ernexa Therapeutics Inc (NASDAQ: ERNA) Right Now?
Company’s 36-month beta value is 5.64.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ERNA is 18.92M, and currently, short sellers hold a 0.55% ratio of that floaft. The average trading volume of ERNA on May 15, 2025 was 221.51K shares.
ERNA’s Market Performance
ERNA’s stock has seen a 19.66% increase for the week, with a 18.74% rise in the past month and a -5.49% fall in the past quarter. The volatility ratio for the week is 12.11%, and the volatility levels for the past 30 days are at 10.60% for Ernexa Therapeutics Inc The simple moving average for the past 20 days is 21.99% for ERNA’s stock, with a -65.73% simple moving average for the past 200 days.
ERNA Trading at 12.70% from the 50-Day Moving Average
After a stumble in the market that brought ERNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.56% of loss for the given period.
Volatility was left at 10.60%, however, over the last 30 days, the volatility rate increased by 12.11%, as shares surge +23.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.36% lower at present.
During the last 5 trading sessions, ERNA rose by +19.66%, which changed the moving average for the period of 200-days by -86.31% in comparison to the 20-day moving average, which settled at $0.2031. In addition, Ernexa Therapeutics Inc saw -15.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ERNA starting from Cherington Charles, who purchase 3,768,397 shares at the price of $0.10 back on Apr 02 ’25. After this action, Cherington Charles now owns 20,401,602 shares of Ernexa Therapeutics Inc, valued at $394,174 using the latest closing price.
Stock Fundamentals for ERNA
Current profitability levels for the company are sitting at:
- -23.58 for the present operating margin
- 0.81 for the gross margin
The net margin for Ernexa Therapeutics Inc stands at -86.16. The total capital return value is set at 2.35. Equity return is now at value -2264.31, with -168.48 for asset returns.
Based on Ernexa Therapeutics Inc (ERNA), the company’s capital structure generated -0.94 points at debt to capital in total, while cash flow to debt ratio is standing at -4.91. The debt to equity ratio resting at -0.48. The interest coverage ratio of the stock is -2.11.
Currently, EBITDA for the company is -36.12 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 30.68. The receivables turnover for the company is 3.43for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
In a nutshell, Ernexa Therapeutics Inc (ERNA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
